In 2021 Dec, company got listed, 22-23 was a bad year for company due to heavy dependency on China and Covid impact. During the last 1-2 quarters, company shifted its focus from China to Regulated markets and that is reflected in margin from geographies. Also Capex spent was slightly delayed in terms of capitalisation by 1-2 quarters.
But a company which is doubling its manufacturing, getting into new markets(and getting traction), doubling its RnD, and also doubling its partnerships (albeit the outcome of partnership will materialise in next 2 years) is a stock to watch out in near future.
Companies which may have a temporary setbacks but have a strong roadmap ahead and is having multiple growth paths are the ones which we might get at a decent valuation.
Beauty lies in the fact that Capex is mostly going to be funded by its internal accruals and minimum debt.
Check this Video, Will give you little more insight about company, Chairman talks about supriya vision and you can see the insides of manufacturing factory -:
Supriya Lifescience Has Big Expansion Plans | Know Your Company | NDTV Profit
Subscribe To Our Free Newsletter |